Regeneron Pharmaceuticals and Sanofi enter sixth amendment to license and collaboration agreement
REGN•Regeneron Pharmaceuticals and Sanofi entered a sixth amendment to their license and collaboration agreement. An in-process research and development charge is expected to reduce Regeneron’s third-quarter 2026 GAAP and non-GAAP earnings per share by $0.18.
1. Expected earnings impact
A filing said an in-process research and development charge is expected to reduce Regeneron’s third-quarter 2026 GAAP and non-GAAP earnings per share by $0.18.
